Rare Cannabinoid Ingredients BayMedica provides high-purity rare cannabinoids for consumer products, creating opportunities for ingredient partnerships with dietary supplements, cosmetics, and food and beverage brands seeking differentiated formulations. Their ongoing product expansion, including the delta 9-dominant THCV launch, signals a pipeline of innovative ingredients open to licensing or private-label deals.

Pharma R&D Partnerships With a portfolio targeting cannabinoid-derived new chemical entities for pharmaceutical applications, BayMedica can collaborate with biotech and pharma companies on early development, research programs, or contract manufacturing of specific cannabinoids for drug discovery or clinical programs.

Strategic Parent Advantage As a division of InMed Pharmaceuticals, BayMedica benefits from corporate backing and potential access to a broader customer base and capital resources for co-selling opportunities and joint go-to-market efforts with INM's footprint.

Capacity & Innovation The company's revenue-stage status and recent product launches indicate an established production capability and a willingness to commercialize new cannabinoids, enabling volume-based partnerships, supply agreements, and scalable manufacturing for customers requiring reliable cannabinoid ingredients.

Collaborative Momentum Existing research partnerships such as the Radicle Science collaboration demonstrate openness to third-party studies and data-backed programs, presenting opportunities for joint research, feasibility studies, and evidence-building collaborations with CROs, universities, and consumer brands.